News AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:16:59 2024-12-12 am EST			5-day change	1st Jan Change
10,489.00 ^GBX	-0.46%		-1.02%	-0.85%

10:15am	Stock market giants pressure suppliers with extreme payment times - Di	FW
Dec. 11	Merck and AstraZeneca unveil long-term Lynparza results	AN

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Stock market giants pressure suppliers with extreme payment times - Di	04:15am	FW
Merck and AstraZeneca unveil long-term Lynparza results	Dec. 11	AN
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients	Dec. 11	MT
LYNPARZA® Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial	Dec. 11	CI
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial	Dec. 11	BU
ASTRAZENECA : Jefferies remains Neutral	Dec. 10	ZD
Global markets live: BlackRock, Apple, Comcast, Boeing, Palantir...	Dec. 09
AstraZeneca - IMFINZI granted Priority Review in the US for patients with muscle-invasive bladder cancer	Dec. 09	AQ
Astrazeneca - Fixed-duration Calquence plus venetoclax demonstrated superior progression-free survival vs. standard of care in previously untreated chronic lymphocytic leukaemia	Dec. 09	AQ
Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia	Dec. 09	MT
Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US	Dec. 09	MT
ASTRAZENECA : Baking in some caution due to the ongoing challenges in China	Dec. 09
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Dec. 09	ZD
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	Dec. 09	BU
AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation	Dec. 09	AN
FTSE 100 : London rises, trailing global markets	Dec. 09
AstraZeneca: receives Breakthrough Therapy designation	Dec. 09	CF
AstraZeneca: promising results in leukemia	Dec. 09	CF
Boohoo gets ISS backing amid Frasers Group spat	Dec. 09	AN
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Receives Breakthrough Designation from US FDA	Dec. 09	MT
AstraZeneca : Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR mutated non small cell lung cancer	Dec. 09	PU
Datopotamab Deruxtecan Grants Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	Dec. 09	CI
AstraZeneca Reports Positive Results from Phase 3 Trial of Leukemia Combination Formulation	Dec. 08	MT
Astrazeneca plc Announces Positive Results from Amplify Phase III Trial	Dec. 08	CI
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial	Dec. 08	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Baking in some caution due to the ongoing challenges in China

December 09, 2024 at 07:38 am EST

Pascal Soriot, CEO of AstraZeneca : New lung cancer treatment shows two-month improvement in survival

September 10, 2024 at 07:48 am EDT